Dwaipayan Mukherjee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4271710/publications.pdf

Version: 2024-02-01

14	285	1039406	1125271
papers	citations	9	13
		h-index	g-index

14	14	14	467
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Physiologicallyâ€Based Pharmacokinetic Models for Evaluating Membrane Transporter MediatedÂDrugâ€“Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. Clinical Pharmacology and Therapeutics, 2020, 107, 1082-1115.	2.3	88
2	Modeling population exposures to silver nanoparticles present in consumer products. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	33
3	Physiologically-Based Toxicokinetic Modeling of Zearalenone and Its Metabolites: Application to the Jersey Girl Study. PLoS ONE, 2014, 9, e113632.	1.1	33
4	Modeling physicochemical interactions affecting in vitro cellular dosimetry of engineered nanomaterials: application to nanosilver. Journal of Nanoparticle Research, 2014, 16, 2616.	0.8	21
5	Dose adjustment of venetoclax when co-administered with posaconazole: clinical drugâ€“drug interaction predictions using a PBPK approach. Cancer Chemotherapy and Pharmacology, 2021, 87, 465-474.	1.1	21
6	Clinical Implications of Altered Drug Transporter Abundance/Function and <scp>PBPK</scp> Modeling in Specific Populations: An <scp>ITC</scp> Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 501-526.	2.3	21
7	Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 443-456.	0.8	17
8	Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 770-781.	2.3	15
9	ModelingIn VitroCellular Responses to Silver Nanoparticles. Journal of Toxicology, 2014, 2014, 1-13.	1.4	12
10	Computational Multiscale Toxicodynamic Modeling of Silver and Carbon Nanoparticle Effects on Mouse Lung Function. PLoS ONE, 2013, 8, e80917.	1.1	9
11	Modeling In Vivo Interactions of Engineered Nanoparticles in the Pulmonary Alveolar Lining Fluid. Nanomaterials, 2015, 5, 1223-1249.	1.9	6
12	In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities. AAPS PharmSciTech, 2019, 20, 243.	1.5	5
13	Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. Biopharmaceutics and Drug Disposition, 2022, 43, 98-107.	1.1	4
14	An Analytical Method for Quantifying Transport and Reaction of Anti-Tumor Drugs in Human Tissues. Journal of Chemical Engineering of Japan, 2009, 42, S226-S233.	0.3	0